

CANCER GENOMICS & PROTEOMICS

online from January 2009



www.cgp-journal.com

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 2 (2005) - VOL. 3 (2006)

VOL. 4 (2007) - VOL. 5 (2008) - VOL. 6 (2009)

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 2-4 months from submission or 1-2 months from acceptance.

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, *^oDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, SIIC.

Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iiar-anticancer.org (Editorial Office); editor@iiar-anticancer.org, editor@cgp-journal.com (Managing Editor)

A Selection of Recent Papers

Secondary Structure at a Hot Spot for DNA Methylation in DNA from Human Breast Cancers. J. CLARK, S.S. SMITH (*Duarte, CA, USA*)

Molecular Mechanisms of Action of Imatinib Mesylate in Human Ovarian Cancer: A Proteomic Analysis. B.B. PATEL, Y.A. HE, X.-M. LI, A. FROLOV, L. VANDERVEER, C. SLATER, R.J. SCHILDER, M. VON MEHREN, A.K. GODWIN, A.T. YEUNG (*Philadelphia, PA; Birmingham, AL, USA*)

Tissue Microarrays of Human Tumor Xenografts: Characterization of Proteins Involved in Migration and Angiogenesis for Applications in the Development of Targeted Anticancer Agents. V. SMITH, G.J. WIRTH, H.-H. FIEBIG, A.M. BURGER (*Freiburg, Germany; Geneva, Switzerland; Detroit, MI, USA*)

Ochratoxin A Lowers mRNA Levels of Genes Encoding for Key Proteins of Liver Metabolism. C. HUNDHAUSEN, C. BOESCH-SAADATMANDI, N. MATZNER, F. LANG, R. BLANK, S. WOLFFRAM, W. BLASCHEK, G. RIMBACH (*Kiel; Tuebingen, Germany*)

Immune Response Signatures of Benzo(α)pyrene Exposure in Normal Human Mammary Epithelial Cells in the Absence or Presence of Chlorophyllin. K. JOHN, C. KESHAVA, D.L. RICHARDSON, A. WESTON, J. NATH (*Morgantown, WV, USA*)

The Protein Expression of TRP-1 and Galectin-1 in Cutaneous Malignant Melanomas. Å. BOLANDER, M. AGNARSDÓTTIR, S. STRÖMBERG, F. PONTEN, P. HESSELIUS, M. UHLEN, M. BERGQVIST (*Uppsala; Stockholm, Sweden*)

Phenotypic Subpopulations of Metastatic Colon Cancer Stem Cells: Genomic Analysis. I.L. BOTCHKINA, R.A. ROWEHL, D.E. RIVADENEIRA, M.S. KARPEH Jr., HOWARD CRAWFORD, A. DUFOUR, J. JU, Y. WANG, Y. LEYFMAN, G.I. BOTCHKINA (*San Francisco, CA; Stony Brook, New York, NY, USA*)

Relative Quantification of Cytochrome P450 1B1 Gene Expression in Peripheral Leukocytes using LightCycler. S. HELMIG, B. HADZAAD, J. DÖHREL, J. SCHNEIDER (*Giessen, Germany*)

Label-free Global Serum Proteomic Profiling Reveals Novel Celecoxib-modulated Proteins in Familial Adenomatous Polyposis Patients. N. FATIMA, D. CHELIUS, B.T. LUKE, M. YI, T. ZHANG, S. STAUFFER, R. STEPHENS, P. LYNCH, K. MILLER, T. GUSZCZYNSKI, D. BORING, P. GREENWALD, I.U. ALI (*Bethesda; Frederick, MD; San Jose, CA; Houston, TX, USA*)

A Gene Expression Profiling Approach Assessing Celecoxib in a Randomized Controlled Trial in Poststate Cancer. P. SOORIAKUMARAN, P. MACANAS-PIRARD, G. BUCCA, A. HENDERSON, S.E.M. LANGLEY, R.W. LAING, C.P. SMITH, E.E. LAING, H.M. COLEY (*Surrey, UK*)

Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. S.M. BOKOBZA, L. YE, H.E. KYNASTON, R.E. MANSEL, W.G. JIANG (*Cardiff, UK*)

Down-regulation of Microfilament Network-Associated Proteins in Leukocytes of Breast Cancer Patients: Potential Application to Predictive Diagnostics. M. BRAUN, M. FOUNTOULAKIS, A. PAPADOPOULOU, K. VOUGAS, I. SEIDEL, T. HÖLLER, K. YEGHIAZARYAN, H.H. SCHILD, W. KUHN, O. GOLUBNITSCHAJA (*Bonn, Germany; Athens, Greece*)

Genomic Analysis of Prostate Cancer Stem Cells Isolated from a Highly Metastatic Cell Line. R.A. ROWEHL, H. CRAWFORD, A. DUFOUR, J. JU, G.I. BOTCHKINA (*Stony Brook, NY, USA*)

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2009 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Interleukin-6 Augments Activation of Liver Regeneration in Porcine Model of Partial Portal Vein Ligation. V. LISKA, V. TRESKA, H. MIRKA, J. KOBR, R. SYKORA, T. SKALICKY, A. SUTNAR, J. BRUHA, O. FIALA, O. VYCITAL, A. CHLUMSKA, L. HOLUBEC, M. MATEJOVIC (<i>Plzen, Czech Republic</i>)	2371
Association of Polymorphisms in <i>Tumor Necrosis Factor Alpha</i> and <i>Beta</i> Genes with Increased Risk for Oral Cancer. C. YAPIJAKIS, Z. SEREFOGLOU, A. VYLLIOTIS, E. NKENKE, S. DERKA, S. VASSILIOU, D. AVGOUSTIDIS, F.W. NEUKAM, E. PATSOURIS, E. VAIRAKTARIS (<i>Athens, Greece; Nürnberg, Germany</i>)	2379
A Novel Method to Display [gal α 1, 3 gal] Antigens on Human Leukemic Cells for Preparation of Anti-leukemia Vaccines. K.J. POSEKANY, J.E. WILEY, G.A. GAGNON (<i>Greenville, NC, USA</i>)	2387
Potent Neutralization of Vacuolating Cytotoxin (VacA) of <i>Helicobacter pylori</i> by Immunoglobulins Against the Soluble Recombinant VacA. M.-R. KI, I.-H. HONG, J.-K. PARK, K.-S. HONG, O.-K. HWANG, J.-Y. HAN, A.-R. JI, S.-I. PARK, S.-K. LEE, S.-E. YOO, K.-S. JEONG (<i>Daegu; Daejeon, South Korea</i>)	2393
Antioxidant and Cyclooxygenase-2-Inhibiting Activity of 4,4'-Biphenol, 2,2'-Biphenol and Phenol. Y. MURAKAMI, H. ISHII, S. HOSHINA, N. TAKADA, A. UEKI, S. TANAKA, Y. KADOMA, S. ITO, M. MACHINO, S. FUJISAWA (<i>Saitama; Tokyo, Japan</i>)	2403
The Sonodynamic Antitumor Effect of Methylene Blue on Sarcoma180 Cells <i>In Vitro</i> . C. KOMORI, K. OKADA, K. KAWAMURA, S. CHIDA, T. SUZUKI (<i>Akita, Japan</i>)	2411
Apurinic/Apyrimidinic Endonuclease (<i>APE1</i>) Gene Polymorphisms and Lung Cancer Risk in Relation To Tobacco Smoking. B. AĞAÇHAN, Ö. KÜÇÜKHÜSEYİN, P. AKSOY, A. TURNA, İ. YAYLIM, U. GÖRMÜŞ, A. ERGEN, Ü. ZEYBEK, B. DALAN, T. İSBİR (<i>Istanbul, Turkey</i>)	2417

* Review (pages 1909, 2031, 2127)

Selective Activity Against Proliferating Tumor Endothelial Cells by CVX-22, A Thrombospondin-1 Mimetic CovX-Body™. J. CORONELLA, L. LI, K. JOHNSON, S. PIRIE-SHEPHERD, G. ROXAS, N. LEVIN (<i>San Diego, CA, USA</i>)	2243
The RING Finger Protein11 Binds to Smad4 and Enhances Smad4-dependant TGF-β Signalling. P.B. AZMI, A.K. SETH (<i>Toronto, ON, Canada</i>)	2253
Estimation of Relationship Between the Structure of 1,2,3,4-Tetrahydroisoquinoline Derivatives Determined by a Semiempirical Molecular-Orbital Method and their Cytotoxicity. M. ISHIHARA, H. HATANO, M. KAWASE, H. SAKAGAMI (<i>Saitama; Ehime, Matsuyama, Japan</i>)	2265
The Characterisation of Flavone-DNA Isoform Interactions as a Basis for Anticancer Drug Development. P.A. RAGAZZON, T. BRADSHAW, C. MATTHEWS, J. ILEY, S. MISSAILIDIS (<i>Milton Keynes; Nottingham, UK</i>) ...	2273
Structure-activity Studies of the Binding of the Flavonoid Scaffold to DNA. P.A. RAGAZZON, J. ILEY, S. MISSAILIDIS (<i>Milton Keynes, UK</i>)	2285
Epigenetic Modifiers Exacerbate Oxidative Stress in Renal Proximal Tubule Cells. E. NADASI, J.S. CLARK, I. SZANYI, T. VARJAS, I. EMBER, R. BALIGA, I. ARANY (<i>Budapest; Pecs, Hungary; Jackson, MS, USA</i>)	2295
Black Tea Polyphenols Target Matrix Metalloproteinases, RECK, Proangiogenic Molecules and Histone Deacetylase in a Rat Hepatocarcinogenesis Model. R.S. MURUGAN, G. VINOTHINI, Y. HARA, S. NAGINI (<i>Tamil Nadu, India; Tokyo, Japan</i>)	2301
The Pathogenetic Mechanism of Anthracycline-induced Palmar-plantar Erythrodysesthesia. A. MARTSCHICK, J. SEHOULI, A. PATZELT, H. RICHTER, U. JACOBI, G. OSKAY-ÖZCELIK, W. STERRY, J. LADEMANN (<i>Berlin, Germany</i>)	2307
Combination Effect between Bortezomib and Tumor Necrosis Factor α on Gefitinib-resistant Non-small Cell Lung Cancer Cell Lines. S. KUSUMOTO, T. SUGIYAMA, K. ANDO, T. HOSAKA, H. ISHIDA, T. SHIRAI, T. YAMAOKA, K. OKUDA, T. HIROSE, T. OHNISHI, F. INOUE, T. KANOME, T. KADOFUKU, N. SAIJO, M. ADACHII, T. OHMORI (<i>Tokyo; Chiba, Japan</i>)	2315
A Role for the Substance P/NK-1 Receptor Complex in Cell Proliferation in Oral Squamous Cell Carcinoma. S. BRENER, M.A. GONZÁLEZ-MOLES, D. TOSTES, F. ESTEBAN, J.A. GIL-MONTOYA, I. RUIZ-ÁVILA, M. BRAVO, M. MUÑOZ (<i>Sao Paulo, Brazil; Granada; Sevilla; Jaen, Spain</i>)	2323
IL-6 and PPARγ Signalling in Human PC-3 Prostate Cancer Cells. N. PITULIS, E. PAPAGEORGIOU, R. TENTA, P. LEMBESSIS, M. KOUTSILIERIS (<i>Athens, Greece</i>)	2331
Proving Tumour Cells by Acute Nutritional/Energy Deprivation as a Survival Threat: A Task for Microscopy. HA. JANECKOVA, P. VESELY, R. CHMELIK (<i>Brno; Prague, Czech Republic</i>)	2339
Breast Tumor Cells Transendothelial Migration Induces Endothelial Cell Anoikis Through Extracellular Matrix Degradation. N. PEYRI, M. BERARD, F. FAUVEL-LAFEVE, V. TROCHON, B. ARBEILLE, H. LU, C. LEGRAND, M. CREPIN (<i>Paris; Tours; Bobigny, France</i>)	2347
Expression of <i>HMGA2-LPP</i> and <i>LPP-HMGA2</i> Fusion Genes in Lipoma: Identification of a Novel Type of <i>LPP-HMGA2</i> Transcript in Four Cases. T. KUBO, Y. MATSUI, N. NAKA, N. ARAKI, T. GOTO, K. YUKATA, K. ENDO, N. YASUI, A. MYOUI, H. KAWABATA, H. YOSHIKAWA, T. UEDA (<i>Tokushima; Osaka, Japan</i>)	2357
Antitumor Effect of Combined Treatment of Mice with Cytostatic Agents and Bacteriophage T4. K. SZCZAURSKA-NOWAK, K. DĄBROWSKA, M. CELKA, A. KURZĘPA, D. NEVOZHAY, J. WIETRZYK, K. ŚWITAŁA-JELEŃ, D. SYPER, G. POŹNIAK, A. OPOLSKI, A. GÓRSKI, C. RADZIKOWSKI (<i>Wrocław; Warsaw; Częstochowa, Poland</i>)	2361

Mechanisms of Escape from Trastuzumab-mediated ADCC in Esophageal Squamous Cell Carcinoma: Relation to Susceptibility to Perforin-granzyme. Y. KAWAGUCHI, K. KONO, Y. MIZUKAMI, K. MIMURA, H. FUJII (<i>Yamanashi, Japan</i>)	2137
The Hedgehog Signaling Pathway Plays an Essential Role in Maintaining the CD44 ⁺ CD24 ^{-low} Subpopulation and the Side Population of Breast Cancer Cells. H. TANAKA, M. NAKAMURA, C. KAMEDA, M. KUBO, N. SATO, S. KUROKI, M. TANAKA, M. KATANO (<i>Fukuoka, Japan</i>)	2147
Antitumor Activity of a Selectively Replication Competent Herpes Simplex Virus (HSV) with Enzyme Prodrug Therapy. L. BRAIDWOOD, P.D. DUNN, S. HARDY, T.R. EVANS, S.M. BROWN (<i>Glasgow, UK</i>)	2159
Differential Effects of Aromatase Inhibitors and Antiestrogens on Estrogen Receptor Expression in Breast Cancer Cells. M. SMOLLICH, M. GÖTTE, J. FISCHGRÄBE, I. RADKE, L. KIESEL, P. WÜLFING (<i>Münster, Germany</i>)	2167
Demonstration of the Activity of P-glycoprotein by a Semi-automated Fluorometric Method. G. SPENGLER, M. VIVEIROS, M. MARTINS, L. RODRIGUES, A. MARTINS, J. MOLNAR, I. COUTO, L. AMARAL (<i>Lisboa; Caparica, Portugal; Szeged, Hungary</i>)	2173
(-)-Gossypol Reduces Invasiveness in Metastatic Prostate Cancer Cells. Y.-W. HUANG, L.-S. WANG, M.K. DOWD, P.J. WAN, Y.C. LIN (<i>Columbus, OH; New Orleans, LA, USA</i>)	2179
Expression of <i>ERas</i> Oncogene in Gastric Carcinoma. R. KAIZAKI, M. YASHIRO, O. SHINTO, K. YASUDA, T. MATSUZAKI, T. SAWADA, K. HIRAKAWA (<i>Osaka, Japan</i>)	2189
Riluzole Induces Apoptotic Cell Death in Human Prostate Cancer Cells <i>via</i> Endoplasmic Reticulum Stress. K. AKAMATSU, M.-A. SHIBATA, Y. ITO, Y. SOHMA, H. AZUMA, Y. OTSUKI (<i>Osaka; Tokyo, Japan</i>)	2195
Osteopontin Modulates Malignant Pleural Mesothelioma Cell Functions <i>In Vitro</i> . R. OHASHI, K. TAJIMA, F. TAKAHASHI, R. CUI, T. GU, K. SHIMIZU, K. NISHIO, K. FUKUOKA, T. NAKANO, K. TAKAHASHI (<i>Tokyo; Osaka; Hyogo, Japan</i>)	2205
Demethylation of the <i>CDH3</i> Gene Is Frequently Detected in Advanced Colorectal Cancer. K. HIBI, T. GOTO, H. MIZUKAMI, Y.-H. KITAMURA, K. SAKURABA, M. SAKATA, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA (<i>Yokohama, Japan</i>)	2215
Expression of Bone Morphogenetic Proteins in Giant Cell Tumor of Bone. N. KUDO, A. OGOSE, T. ARIIZUMI, H. KAWASHIMA, T. HOTTA, H. HATANO, T. MORITA, M. NAGATA, Y. SIKI, A. KAWAI, Y. HOTTA, M. HOSHINO, N. ENDO (<i>Niigata; Tokyo, Japan</i>)	2219
Frequent Methylation of <i>Vimentin</i> in Well-differentiated Gastric Carcinoma. Y.-H. KITAMURA, A. SHIRAHATA, M. SAKATA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI (<i>Yokohama, Japan</i>)	2227
Methylation of <i>HACE1</i> in Gastric Carcinoma. M. SAKATA, Y.-H. KITAMURA, K. SAKURABA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI (<i>Yokohama, Japan</i>)	2231
Demethylation of the <i>CD133</i> Gene Is Frequently Detected in Advanced Colorectal Cancer. K. HIBI, M. SAKATA, Y.-H. KITAMURA, K. SAKURABA, A. SHIRAHATA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA (<i>Yokohama, Japan</i>)	2235
Significant Association of Ku80 Single Nucleotide Polymorphisms with Colorectal Cancer Susceptibility in Central Taiwan. M.-D. YANG, Y.-M. HSU, Y.-S. KUO, H.-S. CHEN, C.-L. CHANG, C.-N. WU, C.-H. CHANG, Y.-M. LIAO, H.-C. WANG, M.-F. WANG, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	2239

Overexpression of Adenovirus-mediated p27 ^{kip1} Lacking the Jab1-binding Region Enhances Cytotoxicity and Inhibits Xenografted Human Cholangiocarcinoma Growth. S. SHIRASO, Y. KATAYOSE, K. YAMAMOTO, M. MIZUMA, S. YABUUCHI, A. ODA, T. RIKIYAMA, T. ONOGAWA, H. YOSHIDA, H. HAYASHI, H. OHTSUKA, F. MOTOI, S. EGAWA, J. KATO, M. UNNO (<i>Sendai; Nara, Japan</i>)	2015
Promoter Demethylation of <i>WIF-1</i> by Epigallocatechin-3-gallate in Lung Cancer Cells. Z. GAO, Z. XU, M.-S. HUNG, Y.-C. LIN, T. WANG, M. GONG, X. ZHI, D.M. JABLON, L. YOU (<i>Beijing, China; San Francisco, CA, USA; Chiayi, Taiwan, ROC</i>)	2025
* Review: Heat-shock Protein 90 (Hsp90) as a Molecular Target for Therapy of Gastrointestinal Cancer. C. MOSER, S.A. LANG, O. STOELTZING (<i>Regensburg; Mainz, Germany</i>)	2031
Identification of $\alpha\beta6$ -Positive Stem Cells in Oral Squamous Cell Carcinoma. D. DANG, D.M. RAMOS (<i>San Francisco, CA, USA</i>)	2043
Decreased Levels of Both Stat1 and Stat3 in T Lymphocytes from Mice Bearing Mammary Tumors. M.E. HANDEL-FERNANDEZ, D. ILKOVITCH, V. IRAGAVARAPU-CHARYULU, L.M. HERBERT, D.M. LOPEZ (<i>Miami; Boca Raton, FL, USA</i>)	2051
Chemopreventive Effect of 4-[3,5-Bis(trimethylsilyl) benzamido] Benzoic Acid (TAC-101) on MNU-induced Colon Carcinogenesis in a Rat Model. Y. NAKAYAMA, Y. INOUE, N. MINAGAWA, K. ONITSUKA, J. NAGATA, K. SHIBAO, K. HIRATA, T. SAKO, N. NAGATA, K. YAMAGUCHI (<i>Kita-Kyushu; Joetsu, Japan</i>)	2059
<i>In Vitro</i> and <i>In Vivo</i> Effects of CpG-Oligodeoxynucleotides (CpG-ODN) on Murine Transitional Cell Carcinoma and on the Native Murine Urinary Bladder Wall. P.J. OLBERT, A.J. SCHRADER, C. SIMON, A. DALPKE, P. BARTH, R. HOFMANN, A. HEGELE (<i>Marburg; Heidelberg, Germany</i>)	2067
Cytoplasmic Accumulation of Glycogen Synthase Kinase-3 β Is Associated with Aggressive Clinicopathological Features in Human Prostate Cancer. R. LI, S. ERDAMAR, H. DAI, M. SAYEEDUDDIN, A. FROLOV, T.M. WHEELER, G.E. AYALA (<i>Houston, TX, USA; Istanbul, Turkey</i>)	2077
Molecular Mechanisms of Sequence-dependent Antitumor Effects of SN-38 and 5-Fluorouracil Combination Therapy against Colon Cancer Cells. S. TORIGOE, Y. OGATA, K. MATONO, K. SHIROUZU (<i>Kurume, Japan</i>)	2083
Latrunculin A Has a Strong Anticancer Effect in a Peritoneal Dissemination Model of Human Gastric Cancer in Mice. H. KONISHI, S. KIKUCHI, T. OCHIAI, H. IKOMA, T. KUBOTA, D. ICHIKAWA, H. FUJIWARA, K. OKAMOTO, C. SAKAKURA, T. SONOYAMA, Y. KOKUBA, H. SASAKI, T. MATSUI, E. OTSUJI (<i>Kyoto; Tokyo, Japan</i>)	2091
An Orally Active Small Molecule TGF- β Receptor I Antagonist Inhibits the Growth of Metastatic Murine Breast Cancer. M.P. RAUSCH, T. HAHN, L. RAMANATHAPURAM, D. BRADLEY-DUNLOP, D. MAHADEVAN, M.E. MERCADO-PIMENTEL, R.B. RUNYAN, D.G. BESSELSSEN, X. ZHANG, H.-K. CHEUNG, W.-C. LEE, L.E. LING, E.T. AKPORIAYE (<i>Tucson, AZ; Portland, OR; Cambridge, MA, USA</i>)	2099
Improvement of Biodistribution and Therapeutic Index <i>via</i> Increase of Polyethylene Glycol on Drug-carrying Liposomes in an HT-29/ <i>luc</i> Xenografted Mouse Model. T.-H. CHOW, Y.-Y. LIN, J.-J. HWANG, H.-E. WANG, Y.-L. TSENG, S.-J. WANG, R.-S. LIU, W.-J. LIN, C.-S. YANG, G. TING (<i>Taipei; Taoyuan, Taiwan, ROC</i>)	2111
Renal Capsule–Parathyroid Lymph Node Complex: A New <i>In Vivo</i> Metastatic Model in Rats. G. TRENCSENYI, P. KERTAI, F. BAKO, J. HUNYADI, T. MARIAN, Z. HARGITAI, I. POCSI, E. MURANYI, L. HORNYAK, G. BANFALVI (<i>Debrecen; Pecs, Hungary</i>)	2121
* Review: Proton Transport Inhibitors as Potentially Selective Anticancer Drugs. S. HARGUINDEY, J.L. ARRANZ, M.L. WAHL, G. ORIVE, S.J. RESHKIN (<i>Vitoria, Spain; Durham, NC, USA; Bari, Italy</i>)	2127

Cleavage of the Ewing Tumour-specific <i>EWSR1-FLII</i> mRNA by Hammerhead Ribozymes. R. HÜHN, M.S. STAEGE, M. HESSE, B. LIEBIG, S.E.G. BURDACH (<i>Halle; München, Germany</i>).....	1901
* Review: Tissue Transglutaminase Promotes or Suppresses Tumors Depending on Cell Context. A. CHHABRA, A. VERMA, K. MEHTA (<i>Houston, TX, USA</i>)	1909
5-Hydroxymethylfurfural and 5-Sulfooxymethylfurfural Increase Adenoma and Flat ACF Number in the Intestine of <i>Min/+</i> Mice. C. SVENDSEN, T. HUSØY, H. GLATT, J.E. PAULSEN, J. ALEXANDER (<i>Oslo, Norway; Nuthetal, Germany</i>).....	1921
Conversion from Calcineurin Inhibitors to Sirolimus Reduces Vascularization and Thickness of Post-transplant Cutaneous Squamous Cell Carcinomas. A.-L. RIVAL-TRINGALI, S. EUVRARD, E. DECULLIER, A. CLAUDY, M. FAURE, J. KANITAKIS (<i>Lyon, France</i>)	1927
Spontaneous Regression of Human Cancer Cells <i>In Vitro</i> : Potential Role of Disruption of Cdk1/Cdk4 Co-expression. H. WARENIUS, L. KYRITSI, I. GRIERSON, A. HOWARTH, L. SEABRA, M. JONES, C. THOMAS, P. BROWNING, R. WHITE (<i>Southampton; Wirral; Liverpool; Surrey; Manchester; Sheffield, UK; Ermoupolis, Greece</i>)	1933
Inhibition of IGF-I Receptor Signaling in Combination with Rapamycin or Temsirolimus Increases MYC-N Phosphorylation. D.W. COULTER, M.B. WILKIE, B.M. MOATS-STAATS (<i>Omaha, NE; Chapel Hill, NC, USA</i>)	1943
Establishment and Characterization of Three Novel Cell Lines – P-ST5, L-ST5, H-ST5 – Derived from a Human Metastatic Midgut Carcinoid. R. PFRAGNER, A. BEHMEL, H. HÖGER, A. BEHAM, E. INGOLIC, I. STELZER, B. SVEJDA, V. AGUIRIANO MOSER, A.C. OBENAUF, V. SIEGL, O. HAAS, B. NIEDERLE (<i>Graz; Himberg; Vienna, Austria</i>)	1951
A Novel Iodomethylene-dimethyl-dihydropyranone Induces G ₂ /M Arrest and Apoptosis in Human Cancer Cells. J. BIGNON, M. BÉNÉCHIE, D. HERLEM, J.-M. LIU, A. PINAULT, F. KHUONG-HUU, J. WDZIECZAK-BAKALA (<i>Gif-sur-Yvette, France</i>)	1963
Ribavirin Acts <i>via</i> Multiple Pathways in Inhibition of Leukemic Cell Proliferation. S. KÖKÉNY, J. PAPP, G. WEBER, T. VASZKÓ, P. CARMONA-SAEZ, E. OLÁH (<i>Budapest, Hungary; Indianapolis, IN, USA; Madrid, Spain</i>).....	1971
Promoted Cell Proliferation by Connexin 30 Gene Transfection to Head-and-Neck Cancer Cell Line. H. OZAWA, H. MUTAI, T. MATSUNAGA, Y. TOKUMARU, M. FUJII, K. SAKAMOTO, T. TOMITA, K. OGAWA (<i>Tokyo, Japan</i>)	1981
Impact of Tumor Cell VEGF Expression on the <i>In Vivo</i> Efficacy of Vandetanib (ZACTIMA™; ZD6474). D.W. SIEMANN, C.M. NORRIS, A. RYAN, W. SHI (<i>Gainesville, FL, USA; Cheshire, UK</i>)	1987
Assessment of Erlotinib in Chemoresponse Assay. S.D. RICE, J.E. BUSH, S.L. BROWER (<i>Pittsburgh, PA, USA</i>)	1993
Prioritization of EGFR/IGF-IR/VEGFR2 Combination Targeted Therapies Utilizing Cancer Models. J.R. TONRA, E. CORCORAN, D.S. DEEVI, P. STEINER, J. KEARNEY, H. LI, D.L. LUDWIG, Z. ZHU, L. WITTE, D. SURGULADZE, D.J. HICKLIN (<i>New York, NY, USA</i>)	1999
14-3-3 σ -Dependent Resistance to Cisplatin. Z. HAN, K. DIMAS, X. TIAN, Y. WANG, H. HEMMI, K. YAMADA, N. KATO, P. PANTAZIS, R.J. RAMANUJAM, S. ANANT, J.H. WYCHE, C.W. HOUCHEM (<i>New York, NY; Oklahoma City, OK; Minneapolis, MN, USA; Athens, Greece; Tokyo, Japan</i>).....	2009